Jinyang Gon, HL Biopharma Chairman, Acquires Additional 100,000 Shares... "Commitment to Responsible Management"

[Asia Economy Reporter Jang Hyowon] Jin Yang-gon, chairman of HL Biopharma, has purchased 100,000 shares of HL Biopharma stock. After announcing a 100% stock dividend in February to enhance shareholder value, he has now directly bought shares on the market, appearing to defend shareholder value.

According to the disclosure on the 17th, Chairman Jin Yang-gon's stake increased from 8.02% (8,510,902 shares) to 8.12% (8,610,902 shares) through the purchase of 100,000 shares on the market. On the 8th, Jin Yang-gon sold all his shares in HL Biopharma Power to TS Bio, and it appears he invested all the proceeds from that sale into this purchase.

Chairman Jin Yang-gon's additional stake acquisition is interpreted as a demonstration of confidence not only in enhancing shareholder value but also in the various new drug development projects being undertaken by the HL Biopharma Group.

At the recently concluded American Society of Clinical Oncology (ASCO 2021), a total of 34 clinical papers on Lenvatinib (Chinese name Apatinib) related to stomach, liver, lung, and gallbladder cancers conducted in China were presented. Additionally, the U.S. subsidiary Immunomic Therapeutics is accelerating clinical trials for the glioblastoma cell therapy vaccine ‘ITI-100’, aiming to complete patient dosing for Phase 2 this year.

An HL Biopharma official stated, “Chairman Jin Yang-gon has been considering a responsible management approach regarding delays in new drug outcomes. This additional share purchase reflects his firm commitment to new drug development as the largest shareholder, alongside enhancing shareholder value.”

This content was produced with the assistance of AI translation services.